Eli Lilly and Company (BKK:LLY80)

Market Cap	22.26T
Revenue (ttm)	1.66T
Net Income (ttm)	377.16B
Shares Out	n/a
EPS (ttm)	417.35
PE Ratio	59.02
Forward PE	29.94
Dividend	0.00 (0.16%)
Ex-Dividend Date	May 16, 2025

Volume	5,313,085
Average Volume	2,113,741
Open	1.230
Previous Close	1.250
Day's Range	1.200 - 1.250
52-Week Range	1.150 - 1.360
Beta	n/a
RSI	39.18
Earnings Date	Aug 7, 2025

About Regulus Therapeutics

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: LLY80

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.